請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/18898完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 陳林祈(Lin-Chi Chen) | |
| dc.contributor.author | Siou-Wei Hu | en |
| dc.contributor.author | 胡修瑋 | zh_TW |
| dc.date.accessioned | 2021-06-08T01:38:48Z | - |
| dc.date.copyright | 2016-09-08 | |
| dc.date.issued | 2016 | |
| dc.date.submitted | 2016-08-26 | |
| dc.identifier.citation | Abdulghani, J., L. Gu, A. Dagvadorj, J. Lutz, B. Leiby, G. Bonuccelli, M. P. Lisanti, T. Zellweger, K. Alanen, T. Mirtti, T. Visakorpi, L. Bubendorf, and M. T. Nevalainen. 2008. Stat3 promotes metastatic progression of prostate cancer. Am. J. Pathol. 172: 1717–1728.
Alexandrow, M. G., L. J. Song, S. Altiok, J. Gray, E. B. Haura, and N. B. Kumar. 2012. Curcumin: a novel Stat3 pathway inhibitor for chemoprevention of lung cancer. Eur. J. Cancer Prev. 21: 407–412. Bharti, A. C., S. shishodia, J. M. Reuben, D. Weber, R. Alexanian, S. Raj-Vadhan, Z. Estrov, M. Talpaz, and B. B. Aggarwal. 2004. Nuclear factor-κB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood. 103: 3175–3184. Bromberg, J. 2002. Stat proteins and oncogenesis. The Journal of Clinical Investigation. 109(9): 1139-1142. Bruno, J. G. 1997. In vitro selection of DNA to chloroaromatics using magnetic microbead-based affinity separation and fluorescence detection. Biochem Biophys Res Commun. 234: 117-120. Cai, L., G. Zhang, X. Tong, Q. You, Y. An, Y. Wang, L. Guo, T. Wang, D. Zhu, and J. Zheng. 2010. Growth inhibition of human ovarian cancer cells by blocking STAT3 activation with small interfering RNA, Eur. J. Obstet. Gynecol. Reprod. Biol. 148: 73–80. Chai, S. K., G. L. Nichols, and P. Rothman. 1997. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J. Immunol. 159: 4720–4728. Chen, C. L., F. C. Hsieh, J. C. Lieblein, J. Brown, C. Chan, J. A. Wallace, G. Cheng, B. M. Hall, and J. Lin. 2007. Stat3 activation in human endometrial and cervical cancers. Br. J. Cancer. 96: 591–599. Chen, R. J., Y. S. Ho, H. R. Guo, and Y. J. Wang. 2008. Rapid activation of Stat3 and ERK1/2 by nicotine modulates cell proliferation in human bladder cancer cells. Toxicol. Sci. 104: 283–293. Corvinus, F. M., C. Orth, R. Moriggl, S. A. Tsareva, S. Wagner, E. B. Pfitzner, D. Baus, R. Kaufmann, L. A. Huber, K. Zatloukal, H. Beug, P. Ohlschlager, A. Schutz, K. J. Halbhuber, and K. Friedrich. 2005. Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia. 7: 545–555. Darnell, J. E., I. M. Kerr, and G. R. Stark. 1994. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 264: 1415-1421. Ellington, A. D., and J. W. Szostak. 1990. In vitro selection of RNA molecules that bind specific ligands. Nature. 346: 818-822. Hbibi, A. T., C. Laguillier, I. Souissi, D. Lesage, S. L. Coquil, A. Cao, V. Metelev, F. Baran-Marszak, and R. Fagard. 2009. Efficient killing of SW480 colon carcinoma cells by a STAT3 hairpin decoy oligodeoxynucleotide – interference with interferon-STAT1-mediated killing. FEBS Journal. 276: 2505-2515. Horiguchi, A., M. Oya, K. Marumo, and M. Murai. 2002. STAT3, but not ERKs mediates the IL-6-induced proliferation of renal cancer cells, ACHN and 769P. Kidney Int. 61: 926-938. Ihle, J.N. 2001. The Stat family in cytokine signaling. Current Opinion in Cell Biology. 13: 211-217. Ishii, Y., S. Waxman, and D. Germain. 2008. Tamoxifen stimulates the growth of Cyclin D1 overexpressing breast cancer cells by promoting the activation of signal transducer and activator of transcription 3. Cancer Res. 68(3): 852-860. James, E., and Jr. Darnell. 1997. STATs and Gene Regulation. Science. 277: 1630-1635. Kypr, J., I. Kejnovska, D. Renciuk, and M. Vorlickova. 2009. Circular dichroism and conformational polymorphism of DNA. Nucleic Acids Research. 37(6): 1713-1725. Jing, M., and M. T. Bowser. 2011. Methods for measuring aptamer-protein equilibria: A review. Analytica Chimica Acta. 686: 9-18. Leong, P. L., G. A. Andrews, D. E. Johnson, K.F. Dyer, S. Xi, J. C. Mai, P. D. Robbins, S. Gadiparthi, N. A. Burke, S. F. Watkins, and J. R. Grandis. 2003. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. PNAS. 100(1): 4138-4143. Ma, Y., X. Zhang, X. Xu, L. Shen, Y. Yao, Z. Yang, P. Liu. 2015. STAT3 Decoy Oligodeoxynucleotides-Loaded Solid Lipid Nanoparticles Induce Cell Death and Inhibit Invasion in Ovarian Cancer Cells. PLOS ONE. doi: 10.1371. Mann, M. J., and V. J. Dzau. 2000. Therapeutic applications of transcription factor decoy oligonucleotides. The Journal of Clinical Investigation. 106(9): 1071-1075. Mendonsa, S. D., and M. T. Bowser. 2004. In vitro evolution of functional DNA using capillary electrophoresis. J Am Chem Soc. 126: 20-21. Nagpal, J. K., R. Mishra, and B. R. Das. 2002. Activation of Stat-3 as one of the early events in tobacco chewing-mediated oral carcinogenesis. Cancer. 94: 2393-2400. Niu, G., T. Bowman, M. Huang, S. Shivers, D. Reintgen, A. Daud, A. Chang, A. Kraker, R. Jove, and H. Yu. 2002. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth, Oncogene. 21: 7001–7010. Rahaman, S.O., P. C. Harbor, O. Chernova, G. H. Barnett, M. A. Vogelbaum, and S. J. Haque. 2002. Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene. 21: 8404–8413. Sadowski, H. B., K. Shuai, J. E. Darnell Jr., and M. Z. Gilman. 1993. A Common Nuclear Signal Transduction Pathway Activated by Growth Factor and Cytokine Receptors. Science. 261(5129): 1739-1744. Schaefer, L. K., Z. Ren, G. N. Fuller, and T. S. Schaefer. 2002. Constitutive activation of Stat3alpha in brain tumors: localization to tumor endothelial cells and activation by the endothelial tyrosine kinase receptor VEGFR-2. Oncogene 2: 2058–2065. Sen, M., S. M. Thomas, S. Kim, J. I. Yeh, R. L. Ferris, J. T. Johnson, U. Duvvuri, J. Lee, N. Sahu, S. Joyce, M. L. Freilino, H. Shi, C. Li D. Ly, S. Rapireddy, J. P. Etter, P. K. Li, L. Wang, S. Chiosea, R. R. Seethala, W. E. Gooding, X. Chen, N. Kaminski, K. Pandit, D. E. Johnson, and J. R. Grandis. 2012. First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. Cancer Discov. 2(8): 694-705. Shen, J., R. Li, and G. Li. 2009. Inhibitory effects of decoy-ODN targeting activated STAT3 on human glioma growth in vivo. in vivo. 23: 237-244. Siveen, K. S., S. Sikka, R. Surana, X. Dai, J. Zhang, A. P. Kumar, B. K. H. Tan, G. Sethi, and A. Bishayee. 2014. Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors. Biochimica et Biophysica Acta. 1845: 136-154. Souissi, I., I. Najjar, L. Ah-Koon. P. O. Schischmanoff, D. Lesage, S. L. Coquil, C. Roger, I. Dusanter-Fourt, N. Varin-Blank, A.Cao, V. Metelev, F. Baran-Marszak, and R. Fagard. 2011. A STAT3-decoy oligonucleotide induces cell death in a human colorectal carcinoma cell line by blocking nuclear transfer of STAT3 and STAT3-bound NF-κB. BMC Cell Biology. 12: 14. Souissi, I., P. Ladam, J. A. Cognet, S. L. Coquil, N. Varin-Blank, F. Baran-Marszak, V. Metelev, and R. Fagard. 2012. A STAT3-inhibitory hairpin decoy oligodeoxynucleotide discriminates between STAT1 and STAT3 and induces death in a human colon carcinoma cell line. Molecular Cancer. 11: 1-12. Stephenson, M. L. and P. C. Zamecnik. 1978.Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Biochemistry. 75(1): 285-288. Sun, X., J. Zhang, L. Wang, and Z. Tian. 2008. Growth inhibition of human hepatocellular carcinoma cells by blocking STAT3 activation with decoy-ODN. Cancer Letters. 262: 201-213. Sun, Z., Z. Yao, S. Liu, H. Tang, and X. Yan. 2006. An oligonucleotide decoy for Stat3 activates the immune response of macrophages to breast cancer. Immunobiology. 211(3): 199-209. Thiel, W. H., T. Bair, A. S. Peek, X. Liu, J. Dassie, and K. R. Stockdale. 2012. Rapid identification of cell-specific, internalizing RNA aptamers with bioinformatics analyses of a cell-base aptamer selection. PLoS One. 7: e43836. Tuerk, C., and L. Gold. 1990. Systematic Evolution of Ligands by Exponential Enrichment: RNA Ligands to Bacteriophage T4 DNA Polymerase. Science. 249: 505-510. Turkson, J., and R. Jove. 2000. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene. 19: 6613-6626. Wang, S. J., Y. T. Hou, and L. C. Chen. 2009.Selective decoy-doxorubicin complex for targeted co-delivery, STAT3 probing and synergistic anti-cancer effect. Chem. Commun. 51(68): 13309-13312. Wei, D., X. Le, L. Zheng, L. Wang, J. A. Frey, A. C. Gao, Z. Peng, S. Huang, H. Q. Xi, S., W. E. Gooding, and J. R. Grandis. 2005. In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy. Oncogene. 24: 970-979. Xiong, J. L. Abbruzzese, and K. Xie. 2003. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene. 22: 319–329. Xiong, A., Z. Yang, Y. Shen, J. Zhou, and Q. Shen. 2014. Transcription factor STAT3 as a novel molecular target for cancer prevention. Cancers. 6: 926-957 Yang, D. K., L. C. Chen, M. Y. Lee, C. H. Hsu, and C. S. Chen. 2014. Selection of aptamers for fliorescent dection of alpha-methylacyl-CoA racemase by single-bead SELEX. Biosensors and Bioelectronics. 62: 106-112. Ye, M., J. Hu, M. Peng, J. Liu, H. Liu, X. Zhao and W. Tan. 2012. Generating Aptamers by Cell-SELEX for Applications in Molecular Medicine. Int. J. Mol. Sci. 13: 3341-3353. You, W., Q. Tang, C. Zhang, J. Wu, C. Gu, Z. Wu, and X. Li. 2013. IL-26 promotes the proliferation and survival of human gastric cancer cells by regulating the balance of STAT1 and STAT3 activation. PLoS ONE, 8(5): 1-9. Yu, H., D. Pardoll, and R. Jove. 2009. STATs in cancer inflammation and immunity: a leading role for STAT3. Nature Reviews. 9: 798-808. Yue, P., and J. Turkson. 2009. Targeting STAT3 in cancer: how successful are we. Expert Opin Investig Drugs. 18(1): 45-56. Zamecnik , P. C. and, M. L. Stephenson. 1978.Inhibition of Rous sarcoma viral replication and cell transformation by a specific oligodeoxynucleotide. Biochemistry. 75(1): 280-284. Zhang, X., J. Zhang, L. Wang, H. Wei, and Z. Tian. 2007. Therapeutic effects of STAT3 decoy oligodeoxynucleotide on human lung cancer in xenograft mice. BMC Cancer. 7: 149. Zhang, X., J. Zhang, H. Wei, and Z. Tian. 2007. STAT3-decoy oligodeoxynucleotide inhibits the growth of human lung cancer via down-regulating its target genes. Oncology Reports. 17: 1377-1382. Zhang, X., P. Liu, B. Zhang, A. Wang, and M. Yang. 2010. Role of STAT3 decoy oligodeoxynucleotides on cell invasion and chemosensitivity in human epithelial ovarian cancer cells. Cancer Genetics and Cytogenetics. 197: 46-53. Zhang, X., P. Liu, B. Zhang, H. Mao, L. Shen, and Y. Ma. 2013. Inhibitory effects of STAT3 decoy oligodeoxynucleotides on human epithelial ovarian cancer cell growth in vivo. International Journal of Molecular Mwdicine. 32: 623-628. Zhang, Y., X. L. Du, C. J. Wang, D. C. Lin, X. Ruan, Y. B. Feng, Y. Q. Huo, H. Peng, J. L. Cui, T. T. Zhang, Y. Q. Wang, H. Zhang, Q. M. Zhan, and M. R. Wang. 2012. Reciprocal activation between PLK1 and STAT3 contributes to survival and proliferation of esophageal cancer cells. Gastroenterology. 142(3): 521-530. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/18898 | - |
| dc.description.abstract | STAT3 (Signal Transducers and Activators of Transcription 3, 訊息傳導及轉錄激活蛋白3) 為細胞中重要的轉錄因子蛋白，當STAT3受到細胞外的訊息分子刺激時，位於細胞質的STAT3會磷酸化以及二聚體化，接著轉位至細胞核後，DNA binding結構域會和目標基因的啟動子上的特定序列鍵結，而轉錄活化該目標基因的表現。STAT3異常的持續活化和許多腫瘤形成有關，因此調控STAT3在癌細胞中的表現具有重要的研究價值。在許多調控方法當中，STAT 3-圈套寡核苷酸 (STAT3-decoy oligonucleotide, STAT3-dODN) 為一段模擬目標基因的啟動子上的特定序列，能與STAT3之DNA binding結構域鍵結，進而抑制STAT3下游基因表現。
本研究的實驗中針對STAT家族的六種蛋白質同時進行篩選，發現此方法適合用於判斷哪種蛋白質會在同時篩選中附著最多的DNA，但是可能並不適合針對每一種STAT蛋白質篩選出對其專一性的DNA序列，此外STAT1蛋白質也許並不適合作為STAT3目標蛋白的反向篩選蛋白質。 在本研究中，將以已知的圈套寡核苷酸候選序列作為篩選的資料庫 (library pool)，STAT3作為目標蛋白，透過系統性配位子指數增益演繹技術 (Systematic Evolution of Ligands by Exponential enrichment, SELEX) 篩選出與STAT3有高度專一性與親合力的適體，並且以ELONA (ELISA-mimic enzyme linked oligonucleotide assay) 驗證篩選獲得的適體之專一性與親合力，透過MTT細胞存活率試驗探討篩選得到的序列對於細胞的影響。在本研究中，找到了具有對STAT3高度親合力的適體序列dODN-18與dODN-20，與過去研究的dODN-pi相比有更高的親合力，同時它們也對細胞的存活率有初步的影響。 | zh_TW |
| dc.description.abstract | Signal transducer and activator of transcription 3 (STAT3) is an important transcription factor in the cell. Abnormal activation of STAT3 has been proven to be a factor leading to cancer cell and regulate cell proliferation, differentiation, apoptosis, immune and inflammatory responses. Since over-activated STAT3 is often found in malignant tumor, it has the strong potential to be a biomarker. STAT3-decoy oligonucleotide (STAT3-dODN) is a specific sequence which is simulate to promoter of target gene. It has ability binding to STAT3 DNA binding domain, and also inhibits the gene expression.
Aptamers, stable single-stranded nucleotides, which have high binding affinity and specificity to target, are selected through Systematic Evolution of Ligands by Exponential enrichment (SELEX). In the study, it shows that it may not be suitable for simultaneous screening of six STAT proteins. In addition, STAT proteins may be not suitable for being each other counter selection protein. In the present study, we demonstrated micro-bead SELEX with different library pool named as N40 and dODN pool. The result showed that we get candidate aptamers in early round of selection (<5). From the ELONA experiment, we get two aptamers named dODN-18 and dODN-20 which have higher affinity to STAT3 protein then dODN-pi. With MTT assay, we also realize the influence of dODN-18 and dODN-20 to cells that it may cause the cell death. Therefore, there are several applications for diagnosis and treatment in the future. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-08T01:38:48Z (GMT). No. of bitstreams: 1 ntu-105-R03631001-1.pdf: 2203242 bytes, checksum: a8dec404add07c10c11370f8dc50157f (MD5) Previous issue date: 2016 | en |
| dc.description.tableofcontents | 目 錄
================= 誌謝………………………………………………………………………………………….. i 中文摘要……………………………………………………………………………………. ii Abstract……………………………………………………………………………………… iii 目錄………………………………………………………………………………………….. iv 圖目錄………………………………………………………………………………………. vi 表目錄………………………………………………………………………………………. viii 第一章 前言…………………………………………………………………………….. 1 1.1 研究背景……………………………………………………………………. 1 1.2 研究動機……………………………………………………………………. 3 1.3 研究目的……………………………………………………………………. 4 1.4 研究架構……………………………………………………………………. 5 第二章 文獻探討……………………………………………………………………… 7 2.1 STAT3與癌症……………………………………………………………… 7 2.2 圈套寡核苷酸……………………………………………………………… 11 2.3 適體與SELEX………………………………………………………………. 17 第三章 實驗設備與方法……………………………………………………………. 20 3.1 實驗儀器與設備………………………………………………………….. 20 3.2 實驗藥品………………………………………………………………………………. 22 3.3 篩選適體使用序列……………………………………………………….. 24 3.4 緩衝溶液配製……………………………………………………………… 25 3.5 蛋白質固定化……………………………………………………………... 26 3.6 篩選步驟……………………………………………………………………. 27 3.7 基因重組……………………………………………………………………. 29 3.8 定序和序列排序………………………………………………………….. 32 3.9 ELONA……………………………………………………………………… 33 3.10 MTT 細胞存活率試驗………………………………………………… 35 3.11 圓二色光譜分析預測適體結構………………………………………. 36 3.12 mfold 分析圈套寡核苷酸構形……………………………………… 36 第四章 結果與討論…………………………………………………………………… 37 4.1 多蛋白質單珠篩選……………………………………………………….. 37 4.2 使用STAT1作為反向篩選蛋白質的可行性………………………. 41 4.3 篩選演化過程 (N40 library pool) …………………………………… 47 4.4 電泳結果分析 (N40 library pool) …………………………………… 52 4.5 篩選演化過程 (dODN library pool)………………………………... 54 4.6 定序結果和序列排序……………………………………………………. 58 4.7 ELONA試驗結果分析…………………………………………………… 67 4.8 MTT細胞存活率試驗結果分析………………………………………. 79 4.9 CD測量與mfold預測結構……………………………………………… 83 第五章 結論…………………………………………………………………………….. 88 第六章 參考文獻………………………………………………………………………. 90 圖目錄 圖 2-1 STAT3之結構域及功能…………………………………………………………….. 7 圖 2-2 STAT3活化之路徑圖………………………………………………………………… 8 圖 2-3 STAT1與STAT3之3D結構比較以及DNA結合區域……………………… 13 圖 2-4 hpdODN-A及其他hpdODN經過設計鹼基的序列…………………………. 13 圖 2-5 hpdODN之mfold預測之構形…………………………………………………….. 16 圖 3-1 SELEX流程示意圖…………………………………………………………………… 27 圖 3-2 ELONA示意圖………………………………………………………................... 34 圖 4-1 多蛋白質單珠篩選qPCR每一回篩選螢光訊號圖…………………………. 39 圖 4-2 STAT1作為反向篩選蛋白質qPCR每一回篩選螢光訊號圖……………. 42 圖 4-3 HSA作為反向篩選蛋白質qPCR每一回篩選螢光訊號圖………………. 45 圖 4-4 N40 library pool qPCR每一循環篩選螢光訊號圖……………................ 47 圖 4-5 電泳分析圖……………………………………………………………………………… 50 圖 4-6 N40 pool每一循環篩選後STAT3和HSA上附著之DNA濃度比……… 51 圖 4-7 SELEX每一循環所得的電泳圖………………………………………………….. 52 圖 4-8 電泳圖中STAT3和HSA以ImageJ分析亮度訊號平均值……………….. 53 圖 4-9 電泳圖中STAT3和HSA以ImageJ分析亮度訊號平均值的比值………. 53 圖4-10 dODN library pool qPCR每一回篩選螢光訊號圖………………………….. 54 圖4-11 dODN pool每一回合篩選後STAT3和HSA上附著之DNA濃度比…… 57 圖4-12 N40 library 篩選出的序列與STAT3結合情形之ELONA試驗………… 67 圖4-13 dODN 序列與STAT3,STAT1,HSA結合情形之ELONA試驗………….. 70 圖4-14 有引子的dODN-18與STAT3,STAT1,thrombin,HAS之ELONA試驗… 72 圖4-15 有引子的dODN-20與STAT3,STAT1,thrombin,HSA之ELONA試驗… 72 圖4-16 無引子的dODN-18與STAT3,STAT1,thrombin,HSA之ELONA試驗… 74 圖4-17 無引子的dODN-20與STAT3,STAT1,thrombin,HSA之ELONA試驗… 74 圖4-18 dODN-pi與STAT3,STAT1,thrombin,HSA結合之ELONA試驗………….. 76 圖4-19 dODN-E與STAT3,STAT1,thrombin,HSA結合之ELONA試驗…………… 76 圖4-20 有引子的dODN-18,dODN-20與無引子的dODN-18,dODN-20和 dODN-pi,dODN-E與STAT3,STAT1,thrombin,HSA之ELONA試驗…… 78 圖4-21 dODN 序列送入MCF-7細胞之MTT試驗存活率圖……………………… 79 圖4-22 dODN序列送入MCF-7細胞不同反應時間之MTT試驗存活率圖…… 80 圖4-23 不同濃度的dODN序列送入MCF-7細胞之MTT試驗存活率圖……… 81 圖4-24 不同的dODN序列有無引子送入MCF-7細胞之MTT試驗存活率圖 82 圖4-25 比較dODN-pi以及有無引子之試體之CD光譜…………………………….. 83 圖4-26 dODN-18, dODN-20有無引子和hpdODN之mofold構形預測………… 85 表目錄 表2-1 STAT3活化與惡性腫瘤之關係…………………………………………………… 9 表2-2 STAT3-dODN序列……………………………………………………………………. 14 表3-1 本研究所使用之儀器、設備規格列表………………………………………….. 20 表3-2 本研究所使用之藥品規格列表…………………………………………………… 22 表3-3 本研究所使用的N40 library pool和primer…………………………………… 24 表3-4 本研究所使用的dODN library pool和primer……………………………….. 24 表4-1 N40 library pool定序結果和其自由能…………………………………………. 58 表4-2 dODN library pool定序結果和其自由能……………………………………… 62 表4-3 N40 library pool序列排序結果…………………………………………………… 65 表4-4 本實驗篩選獲得的序列以及hpdODN序列………………………………….. 84 表4-5 本實驗篩選獲得的序列以及hpdODN序列之鹼基比對………………….. 87 | |
| dc.language.iso | zh-TW | |
| dc.title | 專一性STAT3適體與圈套寡核苷酸之篩選與驗證 | zh_TW |
| dc.title | Selection and Verification of STAT3-specific Aptamers
and Decoy Oligonucleotides | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 104-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 侯詠德(Yung-Te Hou),陳世芳(Shih-Fang Chen),徐駿森(Chun-Hua Hsu) | |
| dc.subject.keyword | 訊息傳導及轉錄激活蛋白3,圈套寡核?酸,適體,系統性配位子指數增益演繹技術, | zh_TW |
| dc.subject.keyword | Signal Transducers and Activators of Transcription 3 (STAT3),decoy oligonucleotide (dODN),aptamer,Systematic Evolution of Ligands by Exponential enrichment (SELEX), | en |
| dc.relation.page | 97 | |
| dc.identifier.doi | 10.6342/NTU201603398 | |
| dc.rights.note | 未授權 | |
| dc.date.accepted | 2016-08-26 | |
| dc.contributor.author-college | 生物資源暨農學院 | zh_TW |
| dc.contributor.author-dept | 生物產業機電工程學研究所 | zh_TW |
| 顯示於系所單位： | 生物機電工程學系 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-105-1.pdf 未授權公開取用 | 2.15 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。